Immunogenicity of, and immunologic memory to, a reduced primary schedule of meningococcal C-tetanus toxoid conjugate vaccine in infants in the United kingdom.
about
Conjugate vaccines for preventing meningococcal C meningitis and septicaemiaConjugate vaccines for preventing meningococcal C meningitis and septicaemiaImmunogenicity of reduced dose priming schedules of serogroup C meningococcal conjugate vaccine followed by booster at 12 months in infants: open label randomised controlled trialMeningococcal conjugate vaccines.Genetic diversity and carriage dynamics of Neisseria lactamica in infantsTiming of an adolescent booster after single primary meningococcal serogroup C conjugate immunization at young age; an intervention study among Dutch teenagersGlobal practices of meningococcal vaccine use and impact on invasive disease.Evaluation of the induction of immune memory following infant immunisation with serogroup C Neisseria meningitidis conjugate vaccines--exploratory analyses within a randomised controlled trial.Is a single dose of meningococcal serogroup C conjugate vaccine sufficient for protection? experience from the Netherlands.Protein carriers of conjugate vaccines: characteristics, development, and clinical trials.Persistence of immune responses after a single dose of Novartis meningococcal serogroup A, C, W-135 and Y CRM-197 conjugate vaccine (Menveo®) or Menactra® among healthy adolescentsResults from a randomized clinical trial of coadministration of RotaTeq, a pentavalent rotavirus vaccine, and NeisVac-C, a meningococcal serogroup C conjugate vaccineMeningococcal conjugate vaccines: optimizing global impact.Mucosal immunology of vaccines against pathogenic nasopharyngeal bacteria.The Potential for Reducing the Number of Pneumococcal Conjugate Vaccine Doses While Sustaining Herd Immunity in High-Income Countries.Avidity of the immunoglobulin G response to a Neisseria meningitidis group C polysaccharide conjugate vaccine as measured by inhibition and chaotropic enzyme-linked immunosorbent assays.Protective meningococcal capsular polysaccharide epitopes and the role of O acetylation.Is a single infant priming dose of meningococcal serogroup C conjugate vaccine in the United Kingdom sufficient?Long-term protection in children with meningococcal C conjugate vaccination: lessons learned.Immunogenicity of a reduced schedule of meningococcal group C conjugate vaccine given concomitantly with the Prevenar and Pediacel vaccines in healthy infants in the United KingdomPersistence of the immune response after MenACWY-CRM vaccination and response to a booster dose, in adolescents, children and infantsPrevention of meningococcal serogroup C disease by NeisVac-C.Correlation between serum bactericidal activity against Neisseria meningitidis serogroups A, C, W-135 and Y measured using human versus rabbit serum as the complement source.Long-term protection after immunization with protein-polysaccharide conjugate vaccines in infancy.Immunogenicity, reactogenicity, and immune memory after primary vaccination with a novel Haemophilus influenzae-Neisseria meningitidis serogroup C conjugate vaccine.Conjugate vaccines.Plasma and memory B-cell kinetics in infants following a primary schedule of CRM 197-conjugated serogroup C meningococcal polysaccharide vaccine.Depressive symptoms and immune response to meningococcal conjugate vaccine in early adolescence.Pneumococcal conjugate vaccine 13 delivered as one primary and one booster dose (1 + 1) compared with two primary doses and a booster (2 + 1) in UK infants: a multicentre, parallel group randomised controlled trial.
P2860
Q24235722-BEE89D86-8A3A-4905-981E-B86240D17D10Q24244951-9A347A4B-2AD5-404A-8B1F-CBC99EAA9D11Q28650557-CC830D3A-E08E-4AF1-814B-C0D9A8C0F517Q30341333-E0BC5FF1-05C9-41F1-A7B0-CE7D67722BC4Q33769344-65B6F861-DAF0-4AAD-BA26-0009053E8F95Q33806774-A8F827B3-A48B-462E-A2E7-FCF9C06F1A19Q33850840-501F2A71-FE7B-46CC-AB23-E419E904D687Q33895627-09B7D919-563A-4847-8E22-1736F99A6F4DQ34153704-60464859-0E60-4D73-A6C0-87278017896AQ34170021-121F5415-F0B4-4B8A-80D2-B72E3EA0C79BQ34694957-5BC61A73-E819-4BCA-9EAD-F25C9F55AFFFQ35066182-C793EAC2-0CFC-49BA-8CBF-FEB986ED2D63Q35547767-922E965E-6AC4-4AF1-9356-17C6ACED7447Q35588006-5CDBD4B2-CEAB-4D83-972D-9943D9379AF9Q35658460-973C6EBE-4058-40A2-ADBC-0569947C199DQ35783483-2F4DFFA1-F4F7-433F-B00F-300D755B83ACQ35783606-7F92C7E0-BE65-4A28-A8C6-44F6AF0CD315Q35887266-87B6527D-BDD1-46C9-99D2-85A12AA8E939Q36690297-8AF8BE8E-D56C-49E7-8139-7B6FF7D4EC1AQ37099242-85DDB13D-4A04-4465-8F3F-BF76987E4922Q37131083-8441B6BE-3A65-430C-8C35-0B981CE950ECQ37403478-F258C6D2-9D72-42A0-9D0F-3C3E6345754EQ37531323-73078AF5-0F8F-4187-9DD5-1A27F831AC48Q37878485-6713CADD-0A77-419F-8D58-95AB0463C2BFQ42800825-80E3580F-801D-46C9-83AE-E28628D6377EQ43098481-DD69F786-BDE9-4587-88F3-83A683FB78C7Q45340766-419BB908-6806-4483-819B-7873A8AE5D77Q47785617-5AAEF6EA-D05C-408C-8A7E-E677B6A0BEA3Q49352945-5A2DF394-FF75-4692-AA0B-32BE6122C61C
P2860
Immunogenicity of, and immunologic memory to, a reduced primary schedule of meningococcal C-tetanus toxoid conjugate vaccine in infants in the United kingdom.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
2003年论文
@zh
2003年论文
@zh-cn
name
Immunogenicity of, and immunol ...... infants in the United kingdom.
@ast
Immunogenicity of, and immunol ...... infants in the United kingdom.
@en
type
label
Immunogenicity of, and immunol ...... infants in the United kingdom.
@ast
Immunogenicity of, and immunol ...... infants in the United kingdom.
@en
prefLabel
Immunogenicity of, and immunol ...... infants in the United kingdom.
@ast
Immunogenicity of, and immunol ...... infants in the United kingdom.
@en
P2093
P2860
P1476
Immunogenicity of, and immunol ...... infants in the United kingdom.
@en
P2093
Christine Riley
Elizabeth Miller
Geraldine Allan
Joanna Southern
Keith Cartwright
Lindsey Ashton
Nick Andrews
Rukhsana Rahim
P2860
P304
P356
10.1128/IAI.71.10.5549-5555.2003
P407
P577
2003-10-01T00:00:00Z